Medifast MED Insider Ownership

Updated Oct 10, 2026

In the last 12 months, insiders at Medifast made open-market purchases of $1.67 million (142.64K shares) and open-market sales of $226,289 (19.09K shares).

• Behind Medifast's open-market trades in the past 12 months were 3 insiders buying and one insider selling.
• Among Medifast's insiders, the largest open-market purchases in the past 12 months were by Parsa Kiai (Director), totaling $1.42 million (119.97K shares), most recently on August 26, 2026.
• On the sell side, Daniel R. Chard (Director) led open-market sales of Medifast stock over the past 12 months with $226,289 (19.09K shares), most recently on September 29, 2026.
• Apart from open-market trades, MED insiders received 114.04K shares in stock awards and gave up 35.56K shares to cover taxes or exercise prices in the past 12 months.
• Business Quant data puts insider holdings in MED at 666.5K shares across insiders' latest Form 4 filings, up 0.18% from 665.32K shares at the end of Q2 2026.
• Direct holdings account for 493.71K shares (74.07%) of MED's insider total, and indirect holdings through trusts, partnerships and family members for 172.79K shares (25.93%).
• The insider holdings in Medifast belong to 10 insiders who have reported on Form 4 within the past two years.
• MED's three largest insider shareholders, per their latest Form 4 filings, are Daniel R. Chard (Director, 336.52K shares), James P. Maloney (Chief Financial Officer, 73.03K shares) and Jeffrey J. Brown (Director, 42.81K shares).
• Daniel R. Chard alone accounts for 50.49% of the shares held by Medifast insiders.
• Institutions accounted for 73.83% of MED's outstanding shares in Q2 2026, insiders about 5.96% per their latest Form 4 filings, and other investors, including the public, about 20.21%.
• A total of 14 Form 4 filings with transactions in Medifast stock were made over the past 12 months, by 9 insiders.
• Insider figures for MED include Form 4 filings through September 30, 2026.